ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1066

Invention and Phenotypic Evaluation of Human IgG4-Knock-in Mice

Yoshie Gon, Hajime Yoshifuji, Koji Kitagori, Toshiki Nakajima, Kosaku Murakami, Ran Nakashima, Koichiro Ohmura and Tsuneyo Mimori, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: IgG4 Related Disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Innate Immunity and Rheumatic Disease Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: IgG4-related disease (IgG4-RD) is a disorder characterized by elevated serum IgG4 concentration and infiltration of IgG4-positive plasma cells into affected organs, however, the role of IgG4 in the pathophysiology of IgG4-RD is not sufficiently elucidated. Although animal models are required, mice only have IgG1, 2 and 3 subclasses but no IgG4. Therefore, we invented human IgG4 (hIgG4)-knock-in (KI) mice and evaluated their phenotypes.

Methods: The hIgG4 gene is inserted in the cite of mouse IgG1 (mIgG1) gene, which is promoted by Th2 cells associated with the pathophysiology of IgG4-RD. In order to preserve the rearrangement system of VDJ region of IgH gene, constant region of hIgG4 gene was only transfected into ES cells of C57BL/6 mice by gene targeting method. 1) We quantitated levels of mRNA extracted from spleens of homozygous (Homo) and heterozygous (Hetero) IgG4-KI mice by quantitative PCR method. 2) Serum IgG4 levels in Homo, Hetero and wild-type (WT) mice were quantitated by ELISA and turbidimetric immunoassay (TIA) used in daily clinics. 3) To enhance the production of IgG4, we established MRL-lpr/IgG4-KI mice and analyzed them by ELISA and flow cytometry (FCM).

Results: 1) Expression of hIgG4 mRNA, mIgG1 mRNA and hIgG4+mIgG1 mRNA were detected in the spleen of Homo, WT and Hetero mice, respectively. 2) hIgG4, mIgG1 and hIgG4+mIgG1 proteins were detected in sera of Homo, WT and Hetero mice, respectively (Fig. 1). Serum hIgG4 level in Homo mice was 7.0 mg/dL by TIA (Table 1). 3) Serum hIgG4 level in MRL-lpr/IgG4-KI Homo mice was increased to 289 mg/dL. We detected the spleen cells that express IgG4 on surface by FCM.

Conclusion: The transfected IgG4 gene seemed to work physiologically, as we confirmed secretory IgG4 in blood and membranous IgG4 on spleen cells in the mice. Serum IgG4 level was high in MRL-lpr/IgG4-KI mice. Their histopathology is to be examined.

Table 1. Serum hIgG4 titer by TIA

 

B6/WT

B6/IgG4-KI Homo

MRL-lpr

MRL-lpr/IgG4-KI

hIgG4 (mg/dL)

Not detected

7.0

Not detected

289


Disclosure: Y. Gon, None; H. Yoshifuji, None; K. Kitagori, None; T. Nakajima, None; K. Murakami, None; R. Nakashima, None; K. Ohmura, None; T. Mimori, None.

To cite this abstract in AMA style:

Gon Y, Yoshifuji H, Kitagori K, Nakajima T, Murakami K, Nakashima R, Ohmura K, Mimori T. Invention and Phenotypic Evaluation of Human IgG4-Knock-in Mice [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/invention-and-phenotypic-evaluation-of-human-igg4-knock-in-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/invention-and-phenotypic-evaluation-of-human-igg4-knock-in-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology